Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 4, 2009, Pages 763-766

  Hegde, Sharath S ^a   Difuntorum, Stacey ^a   Skinner, Robert ^a   Trumbull, Justin ^a   Krause, Kevin M ^a  

^a THERAVANCE INC   (United States)

Author keywords

GISA; Heterogeneous VISA; hVISA; Vancomycin

Indexed keywords

TELAVANCIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTEREMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FEMALE; IMMUNE DEFICIENCY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; BLOOD; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, BACTERIAL; FEMALE; GLYCOPEPTIDES; MICE; SPLEEN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 62549093974     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp001     Document Type: Article

References (12)

1. Appelbaum PC. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2007; 30: 398-408.
2. Pace JL, Krause K, Johnston D et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 3602-4.
3. Higgins DL, Chang R, Debabov DV et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 1127-34.
4. Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58: 338-43.
5. Krause KM, Renelli M, Difuntorum S et al. In vitro activity of telavancin against resistant Gram-positive bacteria. Antimicrob Agents Chemother 2008; 52: 2647-52.
6. Hegde SS, Reyes N, Wiens T et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against Gram-positive bacteria. Antimicrob Agents Chemother 2004; 48: 3043-50.
7. Madrigal AG, Basuino L, Chambers HF. Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillinresistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 3163-5.
8. Reyes N, Skinner R, Kaniga K et al. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 4344-6.
9. Reyes N, Skinner R, Benton BM et al. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58: 462-5.
10. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow AerobicallySeventh Edition: Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2006.
11. Draghi DC, Benton BM, Krause KM et al. Comparative surveillance study of telavancin activity against recently collected Gram-positive clinical isolates from across the United States. Antimicrob Agents Chemother 2008; 52: 2383-8.
12. Draghi DC, Benton BM, Krause KM et al. In vitro activity of telavancin against recent Gram-positive clinical isolates: Results of the 2004-05 Prospective European Surveillance Initiative. J Antimicrob Chemother 2008; 62: 116-21.